1
|
Sidorenko GV, Miroslavov AE, Tyupina MY. Technetium(I) carbonyl complexes for nuclear medicine: Coordination-chemical aspect. Coord Chem Rev 2023. [DOI: 10.1016/j.ccr.2022.214911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
2
|
Kankanamalage PH, Hoerres R, Ho KV, Anderson CJ, Gallazzi F, Hennkens HM. p-NCS-Bn-NODAGA as a bifunctional chelator for radiolabeling with the 186Re/99mTc-tricarbonyl core: Radiochemistry with model complexes and a GRPR-targeting peptide. Nucl Med Biol 2022; 108-109:1-9. [DOI: 10.1016/j.nucmedbio.2022.01.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2021] [Revised: 01/19/2022] [Accepted: 01/27/2022] [Indexed: 12/30/2022]
|
3
|
Thushara N, Darshani T, Samarakoon SR, Perera IC, Fronczek FR, Sameera WMC, Perera T. Synthesis, characterization and biological evaluation of dipicolylamine sulfonamide derivatized platinum complexes as potential anticancer agents. RSC Adv 2021; 11:17658-17668. [PMID: 35480201 PMCID: PMC9033217 DOI: 10.1039/d1ra00842k] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2021] [Accepted: 05/04/2021] [Indexed: 12/22/2022] Open
Abstract
Three new Pt complexes, [PtCl2(N(SO2(2-nap))dpa)], [PtCl2(N(SO2(1-nap))dpa)] and [PtCl2(N(SO2pip)dpa)], containing a rare 8-membered ring were synthesized in good yield and high purity by utilizing the ligands N(SO2(2-nap))dpa, N(SO2(1-nap))dpa and N(SO2pip)dpa, which contain a dipicolylamine moiety. Structural studies of all three complexes confirmed that the ligands are bound in a bidentate mode via Pt–N(pyridyl) bonds forming a rare 8-membered ring. The intense fluorescence displayed by the ligands is quenched upon coordination to Pt. According to time dependent density functional theory (TDDFT) calculations, the key excitations of N(SO2(2-nap))dpa and [PtCl2(N(SO2(1-nap))dpa)] involve the 2-nap-ligand-centered π → π* excitations. While all six compounds have shown antiproliferative activity against human breast cancer cells (MCF-7), the N(SO2pip)dpa and N(SO2(2-nap))dpa ligands and [PtCl2((NSO2pip)dpa)] complex have shown significantly high cytotoxicity, directing them to be further investigated as potential anti-cancer drug leads. Three new Pt complexes, [PtCl2(N(SO2(2-nap))dpa)], [PtCl2(N(SO2(1-nap))dpa)] and [PtCl2(N(SO2pip)dpa)], containing a rare 8-membered ring were synthesized in good yield and high purity by utilizing ligands which contain a dipicolylamine moiety.![]()
Collapse
Affiliation(s)
- Nadini Thushara
- Department of Chemistry, University of Sri Jayewardenepura Sri Lanka
| | - Taniya Darshani
- Department of Chemistry, University of Sri Jayewardenepura Sri Lanka
| | - Sameera R Samarakoon
- Institute of Biochemistry, Molecular Biology and Biotechnology, University of Colombo Sri Lanka
| | - Inoka C Perera
- Department of Zoology and Environment Sciences, University of Colombo Sri Lanka
| | - Frank R Fronczek
- Department of Chemistry, Louisiana State University Baton Rouge LA USA
| | - W M C Sameera
- Institute of Low Temperature Science, Hokkaido University N19-W8, Kita-ku Sapporo Hokkaido 060-0819 Japan
| | - Theshini Perera
- Department of Chemistry, University of Sri Jayewardenepura Sri Lanka
| |
Collapse
|
4
|
Makris G, Bandari RP, Kuchuk M, Jurisson SS, Smith CJ, Hennkens HM. Development and Preclinical Evaluation of 99mTc- and 186Re-Labeled NOTA and NODAGA Bioconjugates Demonstrating Matched Pair Targeting of GRPR-Expressing Tumors. Mol Imaging Biol 2021; 23:52-61. [PMID: 32886303 DOI: 10.1007/s11307-020-01537-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2020] [Revised: 08/10/2020] [Accepted: 08/26/2020] [Indexed: 10/23/2022]
Abstract
PURPOSE The goal of this work was to develop hydrophilic gastrin-releasing peptide receptor (GRPR)-targeting complexes of the general formula fac-[M(CO)3(L)]+ [M = natRe, 99mTc, 186Re; L: NOTA for 1, NODAGA for 2] conjugated to a powerful GRPR peptide antagonist (DPhe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2) via a 6-aminohexanoic acid linker. PROCEDURES Metallated-peptides were prepared employing the [M(OH2)3(CO)3]+ [M = Re, 99mTc, 186Re] precursors. Re-1/2 complexes were characterized with HR-MS. IC50 studies were performed for peptides 1/2 and their respective Re-1/2 complexes in a binding assay utilizing GRPR-expressing human PC-3 prostate cancer cells and [125I]I-Tyr4-BBN as the competing ligand. The 99mTc/186Re-complexes were identified by HPLC co-injection with their Re-analogues. All tracers were challenged in vitro at 37 °C against cysteine/histidine (phosphate-buffered saline 10 mM, pH 7.4) and rat serum. Biodistribution and micro-SPECT/CT imaging of [99mTc]Tc-1/2 and [186Re]Re-2 were performed in PC-3 tumor-bearing ICR SCID mice. RESULTS High in vitro receptor affinity (IC50 2-3 nM) was demonstrated for all compounds. The 99mTc/186Re-tracers were found to be hydrophilic (log D7.4 ≤ - 1.35) and highly stable. Biodistribution in PC-3 xenografted mice revealed good tumor uptake (%ID/g at 1 h: 4.3 ± 0.7 for [99mTc]Tc-1, 8.3 ± 0.9 for [99mTc]Tc-2 and 4.2 ± 0.8 for [186Re]Re-2) with moderate retention over 24 h. Rapid renal clearance was observed for [99mTc]Tc-2 and [186Re]Re-2 (> 84 % at 4 h), indicating favorable pharmacokinetics. Micro-SPECT/CT images for the 99mTc-tracers clearly visualized PC-3 tumors in agreement with the biodistribution data and with superior imaging properties found for [99mTc]Tc-2. CONCLUSIONS [99mTc]Tc-2 shows promise for further development as a GRPR-imaging agent. [186Re]Re-2 demonstrated very similar in vivo behavior to [99mTc]Tc-2, and further studies are therefore justified to explore the theranostic potential of our approach for targeting of GRPR-positive cancers.
Collapse
Affiliation(s)
- George Makris
- Research Reactor Center, University of Missouri, Columbia, MO, 65211, USA
| | - Rajendra P Bandari
- Research Service, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, 65201, USA
| | - Marina Kuchuk
- Research Reactor Center, University of Missouri, Columbia, MO, 65211, USA
| | - Silvia S Jurisson
- Department of Chemistry, University of Missouri, Columbia, MO, 65211, USA
| | - Charles J Smith
- Research Reactor Center, University of Missouri, Columbia, MO, 65211, USA
- Research Service, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, 65201, USA
- Department of Radiology, University of Missouri School of Medicine, Columbia, MO, 65212, USA
| | - Heather M Hennkens
- Research Reactor Center, University of Missouri, Columbia, MO, 65211, USA.
- Department of Chemistry, University of Missouri, Columbia, MO, 65211, USA.
| |
Collapse
|
5
|
Farahani AM, Maleki F, Sadeghzadeh N. The Influence of Different Spacers on Biological Profile of Peptide Radiopharmaceuticals for Diagnosis and Therapy of Human Cancers. Anticancer Agents Med Chem 2020; 20:402-416. [PMID: 31889492 DOI: 10.2174/1871520620666191231161227] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2019] [Revised: 10/07/2019] [Accepted: 12/12/2019] [Indexed: 12/26/2022]
Abstract
BACKGROUND Cancer is the leading cause of death worldwide. Early detection can reduce the disadvantageous effects of diseases and the mortality in cancer. Nuclear medicine is a powerful tool that has the ability to diagnose malignancy without harming normal tissues. In recent years, radiolabeled peptides have been investigated as potent agents for cancer detection. Therefore, it is necessary to modify radiopeptides in order to achieve more effective agents. OBJECTIVE This review describes modifications in the structure of radioconjugates with spacers who have improved the specificity and sensitivity of the peptides that are used in oncologic diagnosis and therapy. METHODS To improve the biological activity, researchers have conjugated these peptide analogs to different spacers and bifunctional chelators. Many spacers of different kinds, such as hydrocarbon chain, amino acid sequence, and poly (ethyleneglycol) were introduced in order to modify the pharmacokinetic properties of these biomolecules. RESULTS Different spacers have been applied to develop radiolabeled peptides as potential tracers in nuclear medicine. Spacers with different charge and hydrophilicity affect the characteristics of peptide conjugate. For example, the complex with uncharged and hydrophobic spacers leads to increased liver uptake, while the composition with positively charged spacers results in high kidney retention. Therefore, the pharmacokinetics of radio complexes correlates to the structure and total charge of the conjugates. CONCLUSION Radio imaging technology has been successfully applied to detect a tumor in the earliest stage. For this purpose, the assessment of useful agents to diagnose the lesion is necessary. Developing peptide radiopharmaceuticals using spacers can improve in vitro and in vivo behavior of radiotracers leading to better noninvasive detection and monitoring of tumor growth.
Collapse
Affiliation(s)
- Arezou M Farahani
- Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Mazandaran, Sari, Iran.,Student Research Committee, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
| | - Fariba Maleki
- Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Mazandaran, Sari, Iran.,Student Research Committee, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
| | - Nourollah Sadeghzadeh
- Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Mazandaran, Sari, Iran
| |
Collapse
|
6
|
Rezazadeh F, Sadeghzadeh N. Tumor targeting with 99m Tc radiolabeled peptides: Clinical application and recent development. Chem Biol Drug Des 2018; 93:205-221. [PMID: 30299570 DOI: 10.1111/cbdd.13413] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2018] [Revised: 08/19/2018] [Accepted: 09/23/2018] [Indexed: 01/16/2023]
Abstract
Targeting overexpressed receptors on the cancer cells with radiolabeled peptides has become very important in nuclear oncology in the recent years. Peptides are small and have easy preparation and easy radiolabeling protocol with no side-effect and toxicity. These properties made them a valuable tool for tumor targeting. Based on the successful imaging of neuroendocrine tumors with 111 In-octreotide, other receptor-targeting peptides such as bombesin (BBN), cholecystokinin/gastrin analogues, neurotensin analogues, glucagon-like peptide-1, and RGD peptides are currently under development or undergoing clinical trials. The most frequently used radionuclides for tumor imaging are 99m Tc and 111 In for single-photon emission computed tomography and 68 Ga and 18 F for positron emission tomography imaging. This review presents some of the 99m Tc-labeled peptides, with regard to their potential for radionuclide imaging of tumors in clinical and preclinical application.
Collapse
Affiliation(s)
- Farzaneh Rezazadeh
- Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.,Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran
| | - Nourollah Sadeghzadeh
- Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
| |
Collapse
|
7
|
Ghosh A, Raju N, Tweedle M, Kumar K. In Vitro Mouse and Human Serum Stability of a Heterobivalent Dual-Target Probe That Has Strong Affinity to Gastrin-Releasing Peptide and Neuropeptide Y1 Receptors on Tumor Cells. Cancer Biother Radiopharm 2017; 32:24-32. [PMID: 28186846 PMCID: PMC5911699 DOI: 10.1089/cbr.2016.2136] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Receptor-targeting radiolabeled molecular probes with high affinity and specificity are useful in studying and monitoring biological processes and responses. Dual- or multiple-targeting probes, using radiolabeled metal chelates conjugated to peptides, have potential advantages over single-targeting probes as they can recognize multiple targets leading to better sensitivity for imaging and radiotherapy when target heterogeneity is present. Two natural hormone peptide receptors, gastrin-releasing peptide (GRP) and Y1, are specifically interesting as their expression is upregulated in most breast and prostate cancers. One of our goals has been to develop a dual-target probe that can bind both GRP and Y1 receptors. Consequently, a heterobivalent dual-target probe, t-BBN/BVD15-DO3A (where a GRP targeting ligand J-G-Abz4-QWAVGHLM-NH2 and Y1 targeting ligand INP-K [ɛ-J-(α-DO3A-ɛ-DGa)-K] YRLRY-NH2 were coupled), that recognizes both GRP and Y1 receptors was synthesized, purified, and characterized in the past. Competitive displacement cell binding assay studies with the probe demonstrated strong affinity (IC50 values given in parentheses) for GRP receptors in T-47D cells (18 ± 0.7 nM) and for Y1 receptors in MCF7 cells (80 ± 11 nM). As a further evaluation of the heterobivalent dual-target probe t-BBN/BVD15-DO3A, the objective of this study was to determine its mouse and human serum stability at 37°C. The in vitro metabolic degradation of the dual-target probe in mouse and human serum was studied by using a 153Gd-labeled t-BBN/BVD15-DO3A and a high-performance liquid chromatography/radioisotope detector analytical method. The half-life (t1/2) of degradation of the dual-target probe in mouse serum was calculated as 7 hours and only ∼20% degradation was seen after 6 hours incubation in human serum. The slow in vitro metabolic degradation of the dual-target probe can be compared with the degradation t1/2 of the corresponding monomeric probes, BVD15-DO3A and AMBA: 15, and ∼40 minutes for BVD15-DO3A and 3.1 and 38.8 hours for AMBA in mouse and human serum, respectively. A possible pathway for in vitro metabolic degradation of the t-BBN/BVD15-DO3A in mouse serum is proposed based on the chromatographic retention times of the intact probe and its degradants.
Collapse
Affiliation(s)
- Arijit Ghosh
- Laboratory for Translational Research in Imaging Pharmaceuticals, The Wright Center of Innovation in Biomedical Imaging, Department of Radiology, The Ohio State University , Columbus, Ohio
| | - Natarajan Raju
- Laboratory for Translational Research in Imaging Pharmaceuticals, The Wright Center of Innovation in Biomedical Imaging, Department of Radiology, The Ohio State University , Columbus, Ohio
| | - Michael Tweedle
- Laboratory for Translational Research in Imaging Pharmaceuticals, The Wright Center of Innovation in Biomedical Imaging, Department of Radiology, The Ohio State University , Columbus, Ohio
| | - Krishan Kumar
- Laboratory for Translational Research in Imaging Pharmaceuticals, The Wright Center of Innovation in Biomedical Imaging, Department of Radiology, The Ohio State University , Columbus, Ohio
| |
Collapse
|
8
|
Feng Y, Phelps TE, Carroll V, Gallazzi F, Sieckman G, Hoffman TJ, Barnes CL, Ketring AR, Hennkens HM, Jurisson SS. Chemistry and radiochemistry of As, Re and Rh isotopes relevant to radiopharmaceutical applications: high specific activity radionuclides for imaging and treatment. Dalton Trans 2017; 46:14677-14690. [DOI: 10.1039/c7dt02407j] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Advances in production, separation, target recovery, and chelation chemistry of high specific activity radionuclides will promote new theranostic agent development.
Collapse
Affiliation(s)
- Yutian Feng
- Department of Chemistry
- University of Missouri
- Columbia
- USA
| | - Tim E. Phelps
- Department of Chemistry
- University of Missouri
- Columbia
- USA
| | | | - Fabio Gallazzi
- Structural Biology Core
- University of Missouri
- Columbia
- USA
| | - Gary Sieckman
- Research Division
- Harry S. Truman Memorial Veterans’ Hospital
- Columbia
- USA
| | | | | | - Alan R. Ketring
- University of Missouri Research Reactor Center (MURR)
- University of Missouri
- Columbia
- USA
| | - Heather M. Hennkens
- University of Missouri Research Reactor Center (MURR)
- University of Missouri
- Columbia
- USA
| | | |
Collapse
|
9
|
Oliveira BL, Blasi F, Rietz TA, Rotile NJ, Day H, Caravan P. Multimodal Molecular Imaging Reveals High Target Uptake and Specificity of 111In- and 68Ga-Labeled Fibrin-Binding Probes for Thrombus Detection in Rats. J Nucl Med 2015; 56:1587-92. [PMID: 26251420 DOI: 10.2967/jnumed.115.160754] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2015] [Accepted: 07/20/2015] [Indexed: 01/19/2023] Open
Abstract
UNLABELLED We recently showed the high target specificity and favorable imaging properties of 64Cu and Al18F PET probes for noninvasive imaging of thrombosis. Here, our aim was to evaluate new derivatives labeled with either with 68Ga, 111In, or 99mTc as thrombus imaging agents for PET and SPECT. In this study, the feasibility and potential of these probes for thrombus imaging was assessed in detail in 2 animal models of arterial thrombosis. The specificity of the probes was further evaluated using a triple-isotope approach with multimodal SPECT/PET/CT imaging. METHODS Radiotracers were synthesized using a known fibrin-binding peptide conjugated to 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid monoamide (DOTA-MA), or a diethylenetriamine ligand (DETA-propanoic acid [PA]), followed by labeling with 68Ga (FBP14, 68Ga-NODAGA), 111In (FBP15, 111In-DOTA-MA), or 99mTc (FBP16, 99mTc(CO)3-DETA-PA), respectively. PET or SPECT imaging, biodistribution, pharmacokinetics, and metabolic stability were evaluated in rat models of mural and occlusive carotid artery thrombosis. In vivo target specificity was evaluated by comparing the distribution of the SPECT and PET probes with preformed 125I-labeled thrombi and with a nonbinding control probe using SPECT/PET/CT imaging. RESULTS All 3 radiotracers showed affinity similar to soluble fibrin fragment DD(E) (inhibition constant=0.53-0.83 μM). After the kidneys, the highest uptake of 68Ga-FBP14 and 111In-FBP15 was in the thrombus (1.0±0.2 percentage injected dose per gram), with low off-target accumulation. Both radiotracers underwent fast systemic elimination (half-life, 8-15 min) through the kidneys, which led to highly conspicuous thrombi on PET and SPECT images. 99mTc-FBP16 displayed low target uptake and distribution consistent with aggregation or degradation. Triple-isotope imaging experiments showed that both 68Ga-FBP14 and 111In-FBP15, but not the nonbinding derivative 64Cu-D-Cys-FBP8, detected the location of the 125I-labeled thrombus, confirming high target specificity. CONCLUSION 68Ga-FBP14 and 111In-FBP15 have high fibrin affinity and thrombus specificity and represent useful PET and SPECT probes for thrombus detection.
Collapse
Affiliation(s)
- Bruno L Oliveira
- Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Harvard Medical School, Massachusetts General Hospital, Charlestown, Massachusetts; and
| | - Francesco Blasi
- Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Harvard Medical School, Massachusetts General Hospital, Charlestown, Massachusetts; and
| | - Tyson A Rietz
- Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Harvard Medical School, Massachusetts General Hospital, Charlestown, Massachusetts; and
| | - Nicholas J Rotile
- Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Harvard Medical School, Massachusetts General Hospital, Charlestown, Massachusetts; and
| | - Helen Day
- Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Harvard Medical School, Massachusetts General Hospital, Charlestown, Massachusetts; and
| | - Peter Caravan
- Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Harvard Medical School, Massachusetts General Hospital, Charlestown, Massachusetts; and Institute for Innovation in Imaging, Massachusetts General Hospital, Boston, Massachusetts
| |
Collapse
|
10
|
Silva F, Campello MPC, Gano L, Fernandes C, Santos IC, Santos I, Ascenso JR, João Ferreira M, Paulo A. Chemical, radiochemical and biological studies of new gallium(iii) complexes with hexadentate chelators. Dalton Trans 2015; 44:3342-55. [DOI: 10.1039/c4dt02274b] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
New Ga3+ complexes with hexadentate chelators were prepared using natural gallium and radiogallium, and showed some favorable features for radiopharmaceutical research.
Collapse
Affiliation(s)
- Francisco Silva
- Centro de Ciências e Tecnologias e Nucleares
- IST
- Universidade de Lisboa
- 2695-066 Bobadela LRS
- Portugal
| | - Maria Paula C. Campello
- Centro de Ciências e Tecnologias e Nucleares
- IST
- Universidade de Lisboa
- 2695-066 Bobadela LRS
- Portugal
| | - Lurdes Gano
- Centro de Ciências e Tecnologias e Nucleares
- IST
- Universidade de Lisboa
- 2695-066 Bobadela LRS
- Portugal
| | - Célia Fernandes
- Centro de Ciências e Tecnologias e Nucleares
- IST
- Universidade de Lisboa
- 2695-066 Bobadela LRS
- Portugal
| | - Isabel C. Santos
- Centro de Ciências e Tecnologias e Nucleares
- IST
- Universidade de Lisboa
- 2695-066 Bobadela LRS
- Portugal
| | - Isabel Santos
- Centro de Ciências e Tecnologias e Nucleares
- IST
- Universidade de Lisboa
- 2695-066 Bobadela LRS
- Portugal
| | - José R. Ascenso
- Centro de Quimica Estrutural
- IST
- Universidade de Lisboa
- Lisboa
- Portugal
| | - M. João Ferreira
- Centro de Quimica Estrutural
- IST
- Universidade de Lisboa
- Lisboa
- Portugal
| | - António Paulo
- Centro de Ciências e Tecnologias e Nucleares
- IST
- Universidade de Lisboa
- 2695-066 Bobadela LRS
- Portugal
| |
Collapse
|
11
|
Abhayawardhana PL, Marzilli PA, Fronczek FR, Marzilli LG. Complexes possessing rare "tertiary" sulfonamide nitrogen-to-metal bonds of normal length: fac-[Re(CO)3(N(SO2R)dien)]PF6 complexes with hydrophilic sulfonamide ligands. Inorg Chem 2014; 53:1144-55. [PMID: 24400928 PMCID: PMC4465231 DOI: 10.1021/ic4026987] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Tertiary sulfonamide nitrogen-to-metal bonds of normal length are very rare. We recently discovered such a bond in one class of fac-[Re(CO)3(N(SO2R)(CH2Z)2)](n) complexes (Z = 2-pyridyl) with N(SO2R)dpa ligands derived from di-(2-picolyl)amine (N(H)dpa). fac-[M(CO)3(N(SO2R)(CH2Z)2)](n) agents (M = (186/188)Re, (99m)Tc) could find use as radiopharmaceutical bioconjugates when R is a targeting moiety. However, the planar, electron-withdrawing 2-pyridyl groups of N(SO2R)dpa destabilize the ligand to base and create relatively rigid chelate rings, raising the possibility that the rare M-N(sulfonamide) bond is an artifact of a restricted geometry. Also, the hydrophobic 2-pyridyl groups could cause undesirable accumulation in the liver, limiting future use in radiopharmaceuticals. Our goal is to identify a robust, hydrophilic, and flexible N(CH2Z)2 chelate framework. New C2-symmetric ligands, N(SO2R)(CH2Z)2 with (Z = CH2NH2; R = Me, dmb, or tol), were prepared by treating N(H)dien(Boc)2, a protected diethylenetriamine (N(H)dien) derivative, with methanesulfonyl chloride (MeSO2Cl), 3,5-dimethylbenzenesulfonyl chloride (dmbSO2Cl), and 4-methylbenzenesulfonyl chloride (tolSO2Cl). Treatment of fac-[Re(CO)3(H2O)3](+) with these ligands, designated as N(SO2R)dien, afforded new fac-[Re(CO)3(N(SO2R)dien)]PF6 complexes. Comparing the fac-[Re(CO)3(N(SO2Me)dien)]PF6 and fac-[Re(CO)3(N(SO2Me)dpa)]PF6 complexes, we find that the Re(I)-N(sulfonamide) bonds are normal in length and statistically identical and that the methyl (13)C NMR signal has an unusually upfield shift compared to that in the free ligand. We attribute this unusual upfield shift to the fact that the sulfonamide N undergoes an sp(2)-to-sp(3) rehybridization upon coordination to Re(I) in both complexes. Thus, the sulfonamide N of N(SO2R)dien ligands is a good donor, even though the chelate rings are conformationally flexible. Addition of the strongly basic and potentially monodentate ligand, 4-dimethylaminopyridine, did not affect the fac-[Re(CO)3(N(SO2tol)dien)]PF6 complex, even after several weeks. This complex is also stable to heat in aqueous solution. These results indicate that N(SO2R)dien ligands form fac-[Re(CO)3(N(SO2R)dien)]PF6 complexes sufficiently robust to be utilized for radiopharmaceutical development.
Collapse
Affiliation(s)
| | - Patricia A. Marzilli
- Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana 70803, United States
| | - Frank R. Fronczek
- Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana 70803, United States
| | - Luigi G. Marzilli
- Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana 70803, United States
| |
Collapse
|
12
|
Radiochemical and radiobiological assessment of a pyridyl-S-cysteine functionalized bombesin derivative labeled with the 99mTc core. Bioorg Med Chem 2013; 21:6699-707. [DOI: 10.1016/j.bmc.2013.08.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2013] [Revised: 07/12/2013] [Accepted: 08/05/2013] [Indexed: 11/19/2022]
|
13
|
Inkster J, Lin KS, Ait-Mohand S, Gosselin S, Bénard F, Guérin B, Pourghiasian M, Ruth T, Schaffer P, Storr T. 2-Fluoropyridine prosthetic compounds for the 18F labeling of bombesin analogues. Bioorg Med Chem Lett 2013; 23:3920-6. [PMID: 23683595 DOI: 10.1016/j.bmcl.2013.04.060] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2013] [Revised: 04/12/2013] [Accepted: 04/22/2013] [Indexed: 12/28/2022]
Abstract
Acetylene-bearing 2-[(18)F]fluoropyridines [(18)F]FPy5yne and PEG-[(18)F]FPyKYNE were prepared via efficient nucleophilic heteroaromatic [(18)F]fluorination of their corresponding 2-trimethylammoniumpyrdinyl precursors. The prosthetic groups were conjugated to azide- and PEG3-modified bombesin(6-14) analogues via copper-catalyzed azide-alkyne cycloaddition couplings to yield mono- and di-mini-PEGylated ligands for PET imaging of the gastrin- releasing peptide receptor. The PEG3- and PEG2/PEG3-bearing (18)F peptides showed decreased lipophilicity relative to an analogous non-mini-PEGylated (18)F peptide. Assessment of water-soluble peptide pharmacokinetics and tumour-targeting capabilities in a mouse model of prostate cancer is currently underway.
Collapse
Affiliation(s)
- James Inkster
- TRIUMF, Nuclear Medicine Division, 4004 Wesbrook Mall, Vancouver, Canada BC V6T 2A3.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Varshney R, Hazari PP, Fernandez P, Schulz J, Allard M, Mishra AK. (68)Ga-labeled bombesin analogs for receptor-mediated imaging. Recent Results Cancer Res 2013; 194:221-256. [PMID: 22918762 DOI: 10.1007/978-3-642-27994-2_12] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Targeted receptor-mediated imaging techniques have become crucial tools in present targeted diagnosis and radiotherapy as they provide accurate and specific diagnosis of disease information. Peptide-based pharmaceuticals are gaining popularity, and there has been vast interest in developing (68)Ga-labeled bombesin (Bn) analogs. The gastrin-releasing peptide (GRP) family and its Bn analog have been implicated in the biology of several human cancers. The three bombesin receptors GRP, NMB, and BRS-3 receptor are most frequently ectopically expressed by common, important malignancies. The low expression of Bn/GRP receptors in normal tissue and relatively high expression in a variety of human tumors can be of biological importance and form a molecular basis for Bn/GRP receptor-mediated imaging. To develop a Bn-like peptide with favorable tumor targeting and pharmacokinetic characteristics for possible clinical use, several modifications in the Bn-like peptides, such as the use of a variety of chelating agents, i.e., acyclic and macrocyclic agents with different spacer groups and with different metal ions (gallium), have been performed in recent years without significant disturbance of the vital binding scaffold. The favorable physical properties of (68)Ga, i.e., short half-life, and the fast localization of small peptides make this an ideal combination to study receptor-mediated imaging in patients.
Collapse
|
15
|
Shen Y, Schottelius M, Zelenka K, De Simone M, Pohle K, Kessler H, Wester HJ, Schmutz P, Alberto R. Orthogonally protected artificial amino acid as tripod ligand for automated peptide synthesis and labeling with [(99m)Tc(OH(2))(3)(CO)(3)](+). Bioconjug Chem 2012; 24:26-35. [PMID: 23237229 DOI: 10.1021/bc3003327] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
1,2-Diamino-propionic acid (Dap) is a very strong chelator for the [(99m)Tc(CO)(3)](+) core, yielding small and hydrophilic complexes. We prepared the lysine based Dap derivative l-Lys(Dap) in which the ε-NH(2) group was replaced by the tripod through conjugation to its α-carbon. The synthetic strategy produced an orthogonally protected bifunctional chelator (BFC). The -NH(2) group of the α-amino acid portion is Fmoc- and the -NH(2) of Dap are Boc-protected. Fmoc-l-Lys(Dap(Boc)) was either conjugated to the N- and C-terminus of bombesin BBN(7-14) or integrated into the sequence using solid-phase peptide synthesis (SPPS). We also replaced the native lysine in a cyclic RGD peptide with l-Lys(Dap). For all peptides, quantitative labeling with the [(99m)Tc(CO)(3)](+) core at a 10 μM concentration in PBS buffer (pH = 7.4) was achieved. For comparison, the rhenium homologues were prepared from [Re(OH(2))(3)(CO)(3)](+) and Lys(Dap)-BBN(7-14) or cyclo-(RGDyK(Dap)), respectively. Determination of integrin receptor binding showed low to medium nanomolar affinities for various receptor subtypes. The IC(50) of cyclo-(RGDyK(Dap[Re(CO)(3)])) for α(v)β(3) is 7.1 nM as compared to 3.1 nM for nonligated RGD derivative. Biodistribution studies in M21 melanoma bearing nude mice showed reasonable α(v)β(3)-integrin specific tumor uptake. Altogether, orthogonally protected l-Lys(Dap) represents a highly versatile building block for integration in any peptide sequence. Lys(Dap)-precursors allow high-yield (99m)Tc-labeling with [(99m)Tc(OH(2))(3)(CO)(3)](+), forming small and hydrophilic complexes, which in turn leads to peptide radiopharmaceuticals with excellent in vivo characteristics.
Collapse
Affiliation(s)
- Yunjun Shen
- Institute of Inorganic Chemistry, University of Zürich, Winterthurerstr. 190, CH-8057 Zürich, Switzerland
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Morais GR, Paulo A, Santos I. Organometallic Complexes for SPECT Imaging and/or Radionuclide Therapy. Organometallics 2012. [DOI: 10.1021/om300501d] [Citation(s) in RCA: 78] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Affiliation(s)
- Goreti Ribeiro Morais
- Unidade de Ciências
Quı́micas e Radiofarmacêuticas, Instituto
Tecnológico e Nuclear, Instituto Superior Técnico, Universidade Técnica de Lisboa, Estrada Nacional
10, 2686-953, Sacavém, Portugal
| | - António Paulo
- Unidade de Ciências
Quı́micas e Radiofarmacêuticas, Instituto
Tecnológico e Nuclear, Instituto Superior Técnico, Universidade Técnica de Lisboa, Estrada Nacional
10, 2686-953, Sacavém, Portugal
| | - Isabel Santos
- Unidade de Ciências
Quı́micas e Radiofarmacêuticas, Instituto
Tecnológico e Nuclear, Instituto Superior Técnico, Universidade Técnica de Lisboa, Estrada Nacional
10, 2686-953, Sacavém, Portugal
| |
Collapse
|
17
|
Fani M, Maecke HR, Okarvi SM. Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Am J Cancer Res 2012; 2:481-501. [PMID: 22737187 PMCID: PMC3364555 DOI: 10.7150/thno.4024] [Citation(s) in RCA: 216] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2011] [Accepted: 03/31/2012] [Indexed: 12/17/2022] Open
Abstract
Human cancer cells overexpress many peptide receptors as molecular targets. Radiolabeled peptides that bind with high affinity and specificity to the receptors on tumor cells hold great potential for both diagnostic imaging and targeted radionuclide therapy. The advantage of solid-phase peptide synthesis, the availability of different chelating agents and prosthetic groups and bioconjugation techniques permit the facile preparation of a wide variety of peptide-based targeting molecules with diverse biological and tumor targeting properties. Some of these peptides, including somatostatin, bombesin, vasoactive intestinal peptide, gastrin, neurotensin, exendin and RGD are currently under investigation. It is anticipated that in the near future many of these peptides may find applications in nuclear oncology. This article presents recent developments in the field of small peptides, and their applications in the diagnosis and treatment of cancer.
Collapse
|
18
|
Liolios CC, Fragogeorgi EA, Zikos C, Loudos G, Xanthopoulos S, Bouziotis P, Paravatou-Petsotas M, Livaniou E, Varvarigou AD, Sivolapenko GB. Structural modifications of ⁹⁹mTc-labelled bombesin-like peptides for optimizing pharmacokinetics in prostate tumor targeting. Int J Pharm 2012; 430:1-17. [PMID: 22459664 DOI: 10.1016/j.ijpharm.2012.02.049] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2011] [Revised: 02/24/2012] [Accepted: 02/26/2012] [Indexed: 10/28/2022]
Abstract
PURPOSE The main goal of the present study was to investigate the importance of the addition of a positively charged aa in the naturally occurring bombesin (BN) peptide for its utilization as radiodiagnostic agent, taking into consideration the biodistribution profile, the pharmacokinetic characteristics and the tumor targeting ability. METHODS Two BN-derivatives of the general structure [M-chelator]-(spacer)-BN(2-14)-NH(2), where M: (99m)Tc or (185/187)Re, chelator: Gly-Gly-Cys-, spacer: -(arginine)(3)-, M-BN-A; spacer: -(ornithine)(3)-, M-BN-O; have been prepared and evaluated as tumor imaging agents. RESULTS The peptides under study presented high radiolabelling efficiency (>98%), significant stability in human plasma (>60% intact radiolabelled peptide after 1h incubation) and comparable receptor binding affinity with the standard [(125)I-Tyr(4)]-BN. Their internalization rates in the prostate cancer PC-3 cells differed, although the amount of internalized peptide was the same. The biodistribution and the dynamic γ-camera imaging studies in normal and PC-3 tumor-bearing SCID mice have shown significant tumor uptake, combined with fast blood clearance, through the urinary pathway. CONCLUSION The addition of the charged aa spacer in the BN structure was advantageous for biodistribution, pharmacokinetics and tumor targeting ability, because it reduced the upper abdominal radioactivity levels and increased tumor/normal tissue contrast ratios.
Collapse
Affiliation(s)
- Christos C Liolios
- Institute of Radioisotopes & Radiodiagnostic Products, NCSR Demokritos, 15310 Athens, Greece.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Kannan R, Pillarsetty N, Gali H, Hoffman TJ, Barnes CL, Jurisson SS, Smith CJ, Volkert WA. Design and synthesis of a bombesin peptide-conjugated tripodal phosphino dithioether ligand topology for the stabilization of the fac-[M(CO)3]+ core (M=(99 m)Tc or Re). Inorg Chem 2011; 50:6210-9. [PMID: 21591746 DOI: 10.1021/ic200491z] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
A new tumor-seeking tridentate topology consisting of a phosphino dithioether ((HOCH(2))(2)PCH(2)CH(2)S(CH(2))(n)CH(2)SR; PS(2)) ligand framework for the production of kinetically inert and in vivo stable facial [(99m)Tc(CO)(3)(PS(2))](+) or [Re(CO)(3)(PS(2))](+) is described. The X-ray crystal structure of fac-Re(CO)(3)(PS(2))PF(6) is reported. The bioconjugation strategies for incorporating bombesin (BBN) peptides on to the PS(2) tripodal framework and, thereby, de novo designing of GRP receptor-seeking Tc(PS(2)-BBN)(CO)(3) are developed.
Collapse
Affiliation(s)
- Raghuraman Kannan
- Department of Radiology, University of Missouri, Columbia, Missouri 65211, USA.
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Maia S, Ayachi Hatit N, Paycha F. [Situation of supply and boom of PET imaging: what is the future for technetium-99m in nuclear medicine?]. ANNALES PHARMACEUTIQUES FRANÇAISES 2011; 69:155-64. [PMID: 21570540 DOI: 10.1016/j.pharma.2011.02.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2010] [Revised: 02/22/2011] [Accepted: 02/25/2011] [Indexed: 12/26/2022]
Abstract
Molecular imaging has shown its interest in the diagnosis, staging and therapy monitoring of many diseases, especially in the field of cancer. This imaging modality can detect non-invasively early molecular changes specific to these diseases. Its expansion includes two aspects linked firstly with the advanced techniques of imaging modalities and secondly with the development of tracers as radio pharmaceuticals for imaging new molecular targets. Technetium-99m ((99m)Tc), because of its physical characteristics, its widespread availability and low cost, is the most used radionuclide in molecular imaging with the technique of single photon emission computed tomography (SPECT). Nevertheless, the current difficulty concerning the supply and the great interest of Positron Emission Tomography (PET), the "competitor" imaging modality-using molecules labelled with fluorine-18 ((18)F), legitimates the question about the future of (99m)Tc, its supremacy and the emergence of new tracer labelled with (99m)Tc. Focusing on the actual and future supply situation, the place of SPECT imaging in nuclear medicine, as well as the development of new molecules labelled with (99m)Tc is necessary to show that this radionuclide will remain essential for the speciality in the next years.
Collapse
Affiliation(s)
- S Maia
- Service de pharmacie et radiopharmacie, hôpital Bretonneau, CHRU de Tours, France.
| | | | | |
Collapse
|
21
|
Mu L, Honer M, Becaud J, Martic M, Schubiger PA, Ametamey SM, Stellfeld T, Graham K, Borkowski S, Lehmann L, Dinkelborg L, Srinivasan A. In vitro and in vivo characterization of novel 18F-labeled bombesin analogues for targeting GRPR-positive tumors. Bioconjug Chem 2011; 21:1864-71. [PMID: 20857927 DOI: 10.1021/bc100222u] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The gastrin-releasing peptide receptor (GRPR) is overexpressed on a number of human tumors and has been targeted with radiolabeled bombesin analogues for the diagnosis and therapy of these cancers. Seven bombesin analogues containing various linkers and peptide sequences were designed, synthesized, radiolabeled with (18)F, and characterized in vitro and in vivo as potential PET imaging agents. Binding studies displayed nanomolar binding affinities toward human GRPR for all synthesized bombesin analogues. Two high-affinity peptide candidates 6b (K(i) = 0.7 nM) and 7b (K(i) = 0.1 nM) were chosen for further in vivo evaluation. Both tracers revealed specific uptake in GRPR-expressing PC-3 tumors and the pancreas. Compared to [(18)F]6b, compound [(18)F]7b was characterized by superior tumor uptake, higher specificity of tracer uptake, and more favorable tumor-to-nontarget ratios. In vivo PET imaging allowed for the visualization of PC-3 tumor in nude mice suggesting that [(18)F]7b is a promising PET tracer candidate for the diagnosis of GRPR-positive tumors in humans.
Collapse
Affiliation(s)
- Linjing Mu
- Center for Radiopharmaceutical Sciences of ETH, PSI and USZ, Zurich, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Correia JDG, Paulo A, Raposinho PD, Santos I. Radiometallated peptides for molecular imaging and targeted therapy. Dalton Trans 2011; 40:6144-67. [DOI: 10.1039/c0dt01599g] [Citation(s) in RCA: 99] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
23
|
Faintuch BL, Núñez GEF, Teodoro R, Moro AM, Mengatti J. Radiolabeled nano-peptides show specificity for an animal model of human PC3 prostate cancer cells. Clinics (Sao Paulo) 2011; 66:327-36. [PMID: 21484054 PMCID: PMC3059864 DOI: 10.1590/s1807-59322011000200024] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/31/2010] [Accepted: 11/09/2010] [Indexed: 03/31/2023] Open
Abstract
OBJECTIVES Cancer has been investigated using various pre-targeting techniques or models focusing on radiobombesin analogues; however, both are not offered together. In this study, nano-bombesin labeling by a pre-targeting system was undertaken to develop an alternative approach for prostate tumor treatment. METHODS A two-step pre-targeting system utilizing a combination of streptavidin (SA), biotinylated morpholino (B-MORF), biotinylated BBN (B-BBN) with two different spacers (b-Ala and PEG), and a radiolabeled cMORF was evaluated in vitro and in vivo. RESULTS Final conjugation conditions consisted of a 1:1:2 ratio of SA:B-MORF:B-BBN, followed by addition of 99mTc-cMORF to compensate for free MORF. In vitro binding experiments with prostate cancer cells (PC-3) revealed that total binding was time-dependent for the Ala spacer but not for the PEG spacer. The highest accumulation (5.06 ± 1.98 %) was achieved with 1 hour of incubation, decreasing as time progressed. Specific binding fell to 1.05 ± 0.35 %. The pre-targeting biodistribution in healthy Swiss mice was measured at different time points, with the best responses observed for 7-h and 15-h incubations. The effector, 99mTc-MAG3-cMORF, was administered 2 h later. Strong kidney excretion was always documented. The greatest tumor uptake was 2.58 ± 0.59 %ID/g at 7 h for B-bAla-BBN, with a region of interest (ROI) value of 3.9 % during imaging. The tumor/blood ratio was low due to the slow blood clearance; however, the tumor/muscle ratio was 5.95. CONCLUSIONS The pre-targeting approach with a peptide was a viable concept. Further evaluation with modified sequences of MORF, including less cytosine, and additional test intervals could be worthwhile.
Collapse
|
24
|
Gourni E, Bouziotis P, Benaki D, Loudos G, Xanthopoulos S, Paravatou-Petsotas M, Mavri-Vavagianni M, Pelecanou M, Archimandritis SC, Varvarigou AD. Structural Assessment and Biological Evaluation of Two N3S Bombesin Derivatives. J Med Chem 2009; 52:4234-46. [DOI: 10.1021/jm900360d] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- Eleni Gourni
- Institutes of Radioisotopes—Radiodiagnostic Products and Biology, NCSR “Demokritos”, 15310 Athens, Greece
| | - Penelope Bouziotis
- Institutes of Radioisotopes—Radiodiagnostic Products and Biology, NCSR “Demokritos”, 15310 Athens, Greece
| | - Dimitra Benaki
- Institutes of Radioisotopes—Radiodiagnostic Products and Biology, NCSR “Demokritos”, 15310 Athens, Greece
| | - George Loudos
- Department of Medical Instruments Technology, Technological Educational Institute of Athens, Athens, Greece
| | - Stavros Xanthopoulos
- Institutes of Radioisotopes—Radiodiagnostic Products and Biology, NCSR “Demokritos”, 15310 Athens, Greece
| | - Maria Paravatou-Petsotas
- Institutes of Radioisotopes—Radiodiagnostic Products and Biology, NCSR “Demokritos”, 15310 Athens, Greece
| | | | - Maria Pelecanou
- Institutes of Radioisotopes—Radiodiagnostic Products and Biology, NCSR “Demokritos”, 15310 Athens, Greece
| | - Spyros C. Archimandritis
- Institutes of Radioisotopes—Radiodiagnostic Products and Biology, NCSR “Demokritos”, 15310 Athens, Greece
| | - Alexandra D. Varvarigou
- Institutes of Radioisotopes—Radiodiagnostic Products and Biology, NCSR “Demokritos”, 15310 Athens, Greece
| |
Collapse
|
25
|
Schottelius M, Wester HJ. Molecular imaging targeting peptide receptors. Methods 2009; 48:161-77. [DOI: 10.1016/j.ymeth.2009.03.012] [Citation(s) in RCA: 146] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2008] [Accepted: 03/11/2009] [Indexed: 02/08/2023] Open
|
26
|
Juran S, Walther M, Stephan H, Bergmann R, Steinbach J, Kraus W, Emmerling F, Comba P. Hexadentate Bispidine Derivatives as Versatile Bifunctional Chelate Agents for Copper(II) Radioisotopes. Bioconjug Chem 2009; 20:347-59. [DOI: 10.1021/bc800461e] [Citation(s) in RCA: 84] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Stefanie Juran
- Forschungszentrum Dresden-Rossendorf, Institute of Radiopharmacy, PF 510119, D-01314 Dresden, Germany, Bundesanstalt für Materialforschung and -prüfung, Richard-Willstätter-Strasse 11, D-12489, Berlin, Germany, and Universität Heidelberg, Anorganisch-Chemisches Institut, Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany
| | - Martin Walther
- Forschungszentrum Dresden-Rossendorf, Institute of Radiopharmacy, PF 510119, D-01314 Dresden, Germany, Bundesanstalt für Materialforschung and -prüfung, Richard-Willstätter-Strasse 11, D-12489, Berlin, Germany, and Universität Heidelberg, Anorganisch-Chemisches Institut, Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany
| | - Holger Stephan
- Forschungszentrum Dresden-Rossendorf, Institute of Radiopharmacy, PF 510119, D-01314 Dresden, Germany, Bundesanstalt für Materialforschung and -prüfung, Richard-Willstätter-Strasse 11, D-12489, Berlin, Germany, and Universität Heidelberg, Anorganisch-Chemisches Institut, Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany
| | - Ralf Bergmann
- Forschungszentrum Dresden-Rossendorf, Institute of Radiopharmacy, PF 510119, D-01314 Dresden, Germany, Bundesanstalt für Materialforschung and -prüfung, Richard-Willstätter-Strasse 11, D-12489, Berlin, Germany, and Universität Heidelberg, Anorganisch-Chemisches Institut, Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany
| | - Jörg Steinbach
- Forschungszentrum Dresden-Rossendorf, Institute of Radiopharmacy, PF 510119, D-01314 Dresden, Germany, Bundesanstalt für Materialforschung and -prüfung, Richard-Willstätter-Strasse 11, D-12489, Berlin, Germany, and Universität Heidelberg, Anorganisch-Chemisches Institut, Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany
| | - Werner Kraus
- Forschungszentrum Dresden-Rossendorf, Institute of Radiopharmacy, PF 510119, D-01314 Dresden, Germany, Bundesanstalt für Materialforschung and -prüfung, Richard-Willstätter-Strasse 11, D-12489, Berlin, Germany, and Universität Heidelberg, Anorganisch-Chemisches Institut, Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany
| | - Franziska Emmerling
- Forschungszentrum Dresden-Rossendorf, Institute of Radiopharmacy, PF 510119, D-01314 Dresden, Germany, Bundesanstalt für Materialforschung and -prüfung, Richard-Willstätter-Strasse 11, D-12489, Berlin, Germany, and Universität Heidelberg, Anorganisch-Chemisches Institut, Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany
| | - Peter Comba
- Forschungszentrum Dresden-Rossendorf, Institute of Radiopharmacy, PF 510119, D-01314 Dresden, Germany, Bundesanstalt für Materialforschung and -prüfung, Richard-Willstätter-Strasse 11, D-12489, Berlin, Germany, and Universität Heidelberg, Anorganisch-Chemisches Institut, Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany
| |
Collapse
|
27
|
Schweinsberg C, Maes V, Brans L, Bläuenstein P, Tourwé DA, Schubiger PA, Schibli R, Garayoa EG. Novel Glycated [99mTc(CO)3]-Labeled Bombesin Analogues for Improved Targeting of Gastrin-Releasing Peptide Receptor-Positive Tumors. Bioconjug Chem 2008; 19:2432-9. [PMID: 19053304 DOI: 10.1021/bc800319g] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Christian Schweinsberg
- Paul Scherrer Institute, Centre for Radiopharmaceutical Science, CH-5232 Villigen PSI, Switzerland, Department of Organic Chemistry, Vrije Universiteit Brussel, 1050 Brussels, Belgium, and Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zurich, Switzerland
| | - Veronique Maes
- Paul Scherrer Institute, Centre for Radiopharmaceutical Science, CH-5232 Villigen PSI, Switzerland, Department of Organic Chemistry, Vrije Universiteit Brussel, 1050 Brussels, Belgium, and Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zurich, Switzerland
| | - Luc Brans
- Paul Scherrer Institute, Centre for Radiopharmaceutical Science, CH-5232 Villigen PSI, Switzerland, Department of Organic Chemistry, Vrije Universiteit Brussel, 1050 Brussels, Belgium, and Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zurich, Switzerland
| | - Peter Bläuenstein
- Paul Scherrer Institute, Centre for Radiopharmaceutical Science, CH-5232 Villigen PSI, Switzerland, Department of Organic Chemistry, Vrije Universiteit Brussel, 1050 Brussels, Belgium, and Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zurich, Switzerland
| | - Dirk A. Tourwé
- Paul Scherrer Institute, Centre for Radiopharmaceutical Science, CH-5232 Villigen PSI, Switzerland, Department of Organic Chemistry, Vrije Universiteit Brussel, 1050 Brussels, Belgium, and Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zurich, Switzerland
| | - P. August Schubiger
- Paul Scherrer Institute, Centre for Radiopharmaceutical Science, CH-5232 Villigen PSI, Switzerland, Department of Organic Chemistry, Vrije Universiteit Brussel, 1050 Brussels, Belgium, and Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zurich, Switzerland
| | - Roger Schibli
- Paul Scherrer Institute, Centre for Radiopharmaceutical Science, CH-5232 Villigen PSI, Switzerland, Department of Organic Chemistry, Vrije Universiteit Brussel, 1050 Brussels, Belgium, and Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zurich, Switzerland
| | - Elisa García Garayoa
- Paul Scherrer Institute, Centre for Radiopharmaceutical Science, CH-5232 Villigen PSI, Switzerland, Department of Organic Chemistry, Vrije Universiteit Brussel, 1050 Brussels, Belgium, and Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zurich, Switzerland
| |
Collapse
|